sur BioNxt Solutions Inc. (CVE:BNXT)
BioNxt's Strategic Move to Gen-Plus Laboratory in Munich
BioNxt Solutions Inc., a bioscience company specializing in advanced drug delivery systems, announced its transition to the Gen-Plus Contract Research and Development Organization in Munich. This move, set for March 1, 2025, aims to accelerate its R&D projects. The new facility offers a 1,000-square-meter research environment, cutting-edge technologies, and strategic collaboration opportunities within Europe's biotech hub.
BioNxt plans to utilize the state-of-the-art equipment for high-potency pharmaceutical ingredients and GMP-compliant processes. This will enhance research capabilities, promote collaborations with leading institutions, and speed up innovation timelines for its projects, including advanced drug delivery systems. CEO Hugh Rogers stated this transition marks a pivotal moment for the company, reinforcing its mission to deliver transformative therapies globally.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioNxt Solutions Inc.